Sarepta Therapeutics, Inc.
Modified antisense oligomers for exon inclusion in spinal muscular atrophy

Abstract:

The present disclosure relates to modified antisense oligomers and related compositions and methods for increasing the expression of functional SMN protein and methods for treating spinal muscular atrophy and relates to inducing inclusion of exon 7 in SMN2 mRNA.